<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01855100</url>
  </required_header>
  <id_info>
    <org_study_id>16852</org_study_id>
    <secondary_id>XA1314BE</secondary_id>
    <nct_id>NCT01855100</nct_id>
  </id_info>
  <brief_title>Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)</brief_title>
  <acronym>BOX-DVT</acronym>
  <official_title>Belgian Real Life Non-interventional Study (NIS) in Patients Treated With XareltoÂ® Following an Acute Deep Vein Thrombosis (DVT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this NIS is to assess in a real-life setting, usage patterns and associated
      outcomes in the management (healthcare resource utilisation and associated costs) of patients
      with acute deep vein thrombosis treated with Xarelto, in accordance with the terms of the
      European marketing authorization and the Belgian reimbursement criteria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with major bleedings</measure>
    <time_frame>up to 1 year or 30 days after end of rivaroxaban</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with symptomatic recurrent Venous Thrombus Embolism (VTE)</measure>
    <time_frame>up to 1 year or 30 days after end of rivaroxaban</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>up to 1 year or 30 days after end of rivaroxaban</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 1 year or 30 days after end of rivaroxaban</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment satisfaction measured by means of Anti-clot treatment scale (ACTS)</measure>
    <time_frame>up to 1 year or 30 days after end of rivaroxaban</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantities of resource use consumption</measure>
    <time_frame>up to 1 year or 30 days after end of rivaroxaban</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">131</enrollment>
  <condition>Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Ambulatory or hospitalized patients coming from the vascular diseases clinic of the
        participating hospitals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with a diagnosis of deep vein thrombosis (DVT) within the past 9
             months, enabling at least 3 months of therapy

        Exclusion Criteria:

          -  Patients who do not fulfil the Belgian reimbursement criteria of deep vein thrombosis
             (DVT)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many locations</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here and search for websynopsis results based on ICH-E3 format.</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2013</study_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment of acute deep vein thrombosis</keyword>
  <keyword>Prevention of recurrence</keyword>
  <keyword>Oral anticoagulation</keyword>
  <keyword>Real-life setting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

